Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (895)	5/25/2001 3:09:32 PM
From: tuck	Read Replies (2) \| Respond to of 1154

Suggest y'all get current: corporate-ir.net This is their latest presentation. They apparently booked a payment recently, because the CEO says they now have $70 million in cash. Claims $200 million in milestone payment "backlog." Investment rate of $10 - $15 (edit: million per year, that is). Per my rhetorical question about one asthma gene, he said they indeed expect to announce a second one, so clearly they're on to the gene clusters concept. Expects to make announcement about osteoporosis gene(s) within the next 18 months. He appears to understand the transition in the sequencing market (if I interpreted his remark about positional cloning correctly), but nobody asked about the center and how it is/expects to be doing. In fact Q&A was dismal. Wish there was an earnings CC I could listen to. Trying to find what Lampert (BVF) saw here. It may well have been undervalued when he found it, and he may have liked the new management team. But I doubt he's expecting $84 in a year. He was already doing pretty well before the dead fish jacked it up. Cheers, Tuck